

Biomarkers and prognostic factors for mesothelioma

Harvey I. Pass

Stephen E. Banner Professor of Thoracic Oncology, Vice-Chair Research, Department of Cardiothoracic Surgery, Division Chief, General Thoracic Surgery, NYU Langone Medical Center, New York, NY 10016, USA

Corresponding to: Harvey I. Pass, MD. Stephen E. Banner Professor of Thoracic Oncology, Vice-Chair Research, Department of Cardiothoracic Surgery, Division Chief, General Thoracic Surgery, NYU Langone Medical Center, 530 First Avenue, 9V, New York, NY 10016, USA. Email: harvey.pass@nyumc.org.

Submitted Sep 13, 2012. Accepted for publication Oct 18, 2012.

DOI: 10.3978/j.issn.2225-319X.2012.10.04

Malignant pleural mesothelioma (MPM) desperately needs non-invasive, accurate prognostication for many reasons: a median survival of 12 months with treatment with first line therapy (1); a median survival of 24 months at best when treated in a multimodal approach with either neoadjuvant chemotherapy and surgery with or without radiation therapy or postoperative chemotherapy (2); a staging system that is not ideal, considering the diffuse nature of the disease and its variable biology (3); difficult, non-R0 surgical cytoreductions that, even with specialized centers have times to progression ranging from 7-12 months, and operative mortalities of 5% (4). MPM patients tend to be older individuals who are frequently functionally impaired and may have difficulty with aggressive therapy; however, there are a cadre of MPM patients who, with favorable biology and a multimodal approach, benefit from intense therapy. Prognostication in MPM must be able to differentiate among patients, hopefully at the time of diagnosis, in whom it is justified to offer potentially hazardous standards of care or novel protocols. If such prognostication implies a short time to death, either palliative therapy or no therapy may be appropriate; however, if prognostic factors indicate that long term survival is possible, a more aggressive approach may be prescribed. Obviously, however, prognostication cannot work in a vacuum and with time prognostication must be closely linked with prediction of response to therapy, in that a patient with a poor prognostic, but predictably sensitive to therapy, tumor may actually benefit from such therapy.

Prognostication in MPM has been approached by studying many variables, usually one at a time, at many centers, all with limited numbers of patients. Univariate and multivariate analyses are performed, yet the majority of the findings remain unvalidated in other MPM

populations. The variables can be purely clinical, such as patient demographics, which are frequently combined with standard laboratory values including white blood cell count or platelet count. Other investigators have concentrated on radiologic parameters at presentation as determined by scrutiny of computerized tomograms (CT) or positron emission tomography (PET) alone or fused with CT. Finally, a molecular pathologic approach, using state of the art platforms such as genomics, microRNA, epigenetics, or proteomics is used in order to define single or combinations of candidate prognostic biomarkers from tissue or blood.

Clinical factors for the prognostication of MPM

The best-known clinical prognostic scoring systems for MPM have originated from European Organisation for Research and Treatment of Cancer (EORTC) and Cancer and Leukemia Group B (CALGB) (5), and use a combination of biological and clinical factors (*Table 1*). Poor performance status, non-epithelioid histology, male gender, low hemoglobin, high platelet count, high white blood cell count, and high lactate dehydrogenase (LDH) were found to be poor prognostic indicators in mesothelioma. The EORTC model was validated at St. Bartholomew's Hospital in a group of 145 patients treated in sequential phase II chemotherapy trials (16). As seen in *Table 1*, there have been a number of mostly retrospective analyses of clinical variables alone or in combination with clinical variables laboratory parameters since the EORTC and CALGB studies were reported. A recurring theme in patients who have not had surgical resection includes non-epithelial histotype, low hemoglobin, and high WBC as poor prognostic indicators in these studies. As a follow-up

Table 1 Clinical prognostic studies

Marker	Year	Author	N	Data: univariate predictors	Multivariate
Lab/Clinical: Japan	2011	Nojiri (6)	314	Demographic and laboratory parameters	Age >70, non-epithelial, low PS, high WBC, high CRP
Lab/Clinical: Turkey	2010	Tanrikulu (7)	363	Glucose <40, CRP >50: ↓survival	KPS, serum LDH, presence of pleural effusion, pleural thickening >1 cm, and PLT >420k
Clinical	2010	Richards (8)	354	Stratification of T and N status, epithelial only	N2b vs. N2a nodal status with different Hazard Ratio
EORTC prognostic index for PFS	2009	Francart (9)	523	PS >0, Stage IV, non-epithelial: ↓PFS	Age, histotype, stage, PS, hgb, WBC
Lab/Clinic surgical series of EPP, PD, biopsy	2009	Yan (10)	456	Young age, pleural effusion, epithelial, EPP, PET scan, adjuvant therapy: ↑survival	Epithelial and EPP: ↑survival
Clinical/Laboratory: Turkey	2008	Gonlugur (11)	71	Pleural fluid glucose levels, the ratio of pleural fluid to serum LDH >1.0, and total leukocyte count predict OS	None of the factors were predictive
Clinical	2007	Flores (12)	945	Histology, gender, smoking, asbestos exposure, laterality, surgical resection by EPP or PD, American Joint Committee on Cancer stage, and symptoms	Surgical resection, non smokers, female, no pain, epithelial, left side: ↑survival
Clinical	2005	Steele (13)	145	EORTC prognostic Index: PS, non-epithelial, male, low hgb, high platelet count, high WBC, high LDH: ↓survival	PS, WBC, hgb, uncertain diagnosis, sarcomatoid: ↓survival
Clinical	2004	Neumann (14)	155	Epithelial, young age, female gender: ↑survival	Epithelial, young age, female gender: ↑survival
EORTC and CALGB prognostic indices	2000	Edwards (5)	142	Male sex, older age, weight loss, chest pain, poor performance status, low hgb, leukocytosis, thrombocytosis, and non-epithelial cell type: ↓survival	Cell type, hgb, white cell count, performance status, and sex
Clinical	1998	Herndon (15)	337	CALGB prognostic Index: PS, chest pain, dyspnea, PLT >400,000/uL, weight loss, serum LDH level >500 IU/L, pleural involvement, low hgb level, high WBC count, and increasing age over 75 years	Pleural involvement, LDH > 500 IU/L, poor PS, chest pain, PLT >400,000, nonepithelial histology, and increasing age older than 75 years

on the EORTC data, a prognostic index for progression free survival revealed that age, histotype, stage, performance status, hemoglobin (9) and WBC levels were independent

predictors time to progression. For MPM patients undergoing surgical resection, an IASLC/International Mesothelioma Interest Group sponsored retrospective

Table 2 Radiographic prognostic studies

Marker	Year	Author	N	Data: univariate predictors	Multivariate
CT volume	2012	Gill (17)	88	Tumor volume predicts survival after EPP	Tumor volume, hgb, adjuvant therapy
PET-CT	2011	Sharif (18)	1108	High SUV >10: ↓survival. Best evidence review 15 papers	NA
PET-CT volume	2010	Lee (19)	13	High MTV and TLG: ↓survival	MTV and TLG
Quantitative FDG	2010	Nowak (20)	89	High TGV histology, weight loss, CT stage, EORTC prognostic score: ↓survival	TGV and weight loss for non-sarcomatoid

PS, performance status; WBC, white blood cells; CRP, c-reactive protein; KPS, karnofsky performance status; EORTC, European Organization for Research and Treatment of Cancer; PFS, progression free survival; hgb, hemoglobin; EPP, extrapleural pneumonectomy; PD, pleurectomy/decortication; OS, overall survival; LDH, lactate dehydrogenase; PLT, platelet count; NA, not applicable; MTV, metabolic tumor volume; SUV, standardized uptake value; TLG, total lesion glycolysis; FDG, fluoro-D-glucose; TGV, total glycolytic volume

registry of 3,101 patients from 15 centers on 4 continents has described “core” prognostic variables as stage, histotype, gender, age, and treatment intent (curative or palliative) (Rusch *in press*). The prognostic significance of other demographic factors including adjuvant therapy, WBC, hgb, smoking history, asbestos history, performance status, chest pain, and weight loss are also being investigated.

Radiographic and nuclear imaging prognostic studies in mesothelioma

Quantification of the standardized uptake value (SUV) for PET scanning as well as novel CT techniques have also been investigated in mesothelioma for prognostic reliability (Table 2). Low SUV and epithelial histology predict the best survival, whereas high SUV and nonepithelial histology indicate the worst survival. In a multivariate analysis of 65 patients with MPM, median survival was 14 and 24 months for the high and low SUV groups, respectively. High SUV tumors were associated with 3.3 times greater risk of death than low SUV tumors ($P=0.03$) (21). Gerbaudo *et al.* (22) reported that the intensity of FDG uptake by mesothelioma correlates poorly with histology, but well with surgical stage. A recent “best evidence” report from Sharif *et al.* (18) addressed whether PET is useful in the diagnosis and prognosis of MPM. Altogether only 15 of 136 papers represented the best evidence studies, and these revealed that malignant disease had a higher SUV (6.5 ± 3.4 vs. 0.8 ± 0.6 ; $P<0.001$) than benign pleural disease. Shorter median survival (9.7 vs. 21 months; $P=0.02$) was associated with high SUV (>10) compared to low SUV (<10). Overall, PET accurately diagnoses MPM

and predicts survival and disease recurrence. With both PET as well as computerized tomographic studies, there has been an increasing emphasis on the role of volume measurements as a prognostic variable. In a study by Nowak *et al.* (20), volumetric FDG-PET parameters were more predictive of survival than tumor-node-metastasis staging in patients with non-sarcomatoid disease, suggesting that tumor volume and glycolytic activity may be more important determinants of prognosis in malignant pleural mesothelioma than anatomic extent of disease. Sarcomatoid histology, however, remained the strongest prognostic factor. In a study by Lee *et al.* (19), multivariate analysis adjusted for treatment modality showed that metabolic tumor volume and total lesion glycolysis were independent factors associated with tumor progression. Time to tumor progression was shorter in patients with a high volume-based parameter of PET than in those with a low value. Following up on earlier studies by Pass *et al.* (23) regarding the influence of tumor volume of survival and progression of surgically treated mesothelioma patients, Gill *et al.* (17) reported that CT-derived tumor volume can be used to stratify survival of 88 patients with epithelial mesothelioma after extrapleural pneumonectomy. In univariate analysis, tumor volume, hemoglobin concentration, platelet count, pathologic TNM category, and administration of adjuvant chemotherapy or radiation therapy met the criteria for inclusion in the reverse stepwise regression analysis. In the final model, tumor volume, hemoglobin concentration, and administration of adjuvant chemotherapy or radiotherapy were identified as independently associated with overall survival. Further multicenter validation of these CT volume findings is planned.

Table 3 Molecular prognostic factors					
Marker	Year	Author	N	Data: univariate predictors	Multivariate
CEC	2012	Yoneda (24)	109	CEC, intratumoral vessel density	CEC independently predict prognosis
Clinical factors and NLR validation	2012	Kao (25)	148	Younger age, epithelial subtype, lower tumor stage, low white cell count, low platelet count, low hemoglobin level, and low NLR: ↑survival	Nonepithelial vs. epithelial subtype tumor stage, hgb level, no chemotherapy vs. use of chemotherapy, and NLR ≥3 vs. <3
PTEN and NLR	2012	Cedr�s (26)	30	PTEN pathway IHC proteins only pS6	Histology and NLR only
Tumor IL4Rα	2012	Burt (27)	37	Tumor PCR IL4Rα, age, sex, stage	Tumor IL4Rα independently prognostic
CD26	2012	Aoe (28)	79	Age, histology, EPP, chemotherapy, BSC, CD26 expression	CD26 was not an independent predictor of survival
c-MET membrane staining	2012	Levallet (29)	157	Age, histological subtype, the c-MET and phospho-c-MET intensities, the c-MET localization, and the c-MET scoring	Histological subtype, c-MET intensity, and age
Aquaporin1	2011	Kao (30)	136	Tumor overexpression: ↑survival	Aquaporin, age, sex, histology
Calretinin and NLR	2011	Kao (31)	85	High calretinin /low NLR: ↑survival	Calretinin and NLR
NLR	2011	Kao (32)	173	NLR <5: ↓survival	Histotype and NLR
Nuclear Grade	2011	Kadota (33)	232	Epithelial Nuclear atypia & mitotic count (nuclear grade)	R Laterality, lymphatic invasion, nuclear grade: ↓survival
Circulating/tumor infiltrating myeloid cells	2011	Burt (34)	667	High monocyte counts: ↓survival; high macrophages: ↓survival in non epithelial	Yes, but monocyte data and histology only considered
Serum EGFr	2010	Gaafar (35)	71	Serum/tissue EGFr not prognostic	Not predictive
NTS	2010	Alifano (36)	52	NTS High Expression: ↓survival	NTS High Expression and non surgical therapy: ↓survival
EMT	2010	Schramm (37)	352	EGFr, integrin beta, nuclear p27, perisotin: non Epithelial, no therapy, high expression periostin, NTS High Expression: ↓survival	Any therapy, low cytoplasmic periostin, high PTEN: ↑survival
Mir-29c*	2010	Pass (38)	120	Higher levels of tumor mir: ↑survival	Mir-29c*, early Stage, and Chemotherapy use: ↑survival
PLGF	2009	Pompeo (39)	27	High PLGF: ↓survival	Not predictive
Gene expression	2009	Gordon (40)	120	Gene Expression Ratio cut offs predict overall survival	Lymph node, histology, expression ratio
SMRP	2008	Schneider (41)	100	SMRP	SMRP not indepent predictor in epithelial
Mesothelin	2008	Roe (42)	47	Low mesothelin expression: ↓survival	No
Pathologic	2008	Christensen (43)	208	Male, non epithelial, high lung fiber burden: ↓survival	Only asbestos burden
Pathology marker	2008	Baldi (44)	70	Higher tissue expression of HtrA1: ↑survival; higher tissue expression of EGFR: ↑survival	HtrA1, T Stage
Tissue EGFr	2007	Edwards (45)	168	EGFr expression: ↑survival	Not predictive

Table 3 (Continued)

Table 3 (Continued)

Marker	Year	Author	N	Data: univariate predictors	Multivariate
SMRP/osteopontin	2007	Grigoriu (46)	172	Stage, serum and plasma SMRP and osteopontin	Serum SMRP and serum osteopontin
Gene expression	2006	Lopez-Rios (47)	99	Aurora Kinase expression: ↓survival Expression arrays not predictive	Stage, histology, p16 deletion
TN/MVC	2003	Edwards (48)	171	TN: ↓survival	Non epithelial, increasing MVC, PS: ↓survival; not TN
Cox-2 and p27 and p21	2004	Baldi (49)	29	p21, p27 and COX-2: ↓survival	Only Cox-2 but no clinical factors considered
Cox 2	2002	Edwards (50)	48	Cox2: ↓survival	Cox2, non epithelial, chest pain: ↓survival
Angiogenesis MVD	2001	Edwards (51)	104	Non epithelial, MVD, PS: ↓survival	Non epithelial, MVD, PS: ↓survival
Biomarker SV40 sequences	2000	Procopio (52)	83	Epithelial and SV40 negative: ↑survival	Gender, age, SV40 status
Biomarker	1999	Ohta (53)	54	VEGC, FLT, KDR, LVD, VD	Male, advanced stage, high VD: ↓survival
Biomarkers Cyfra 21-1, TPA	1999	Schouwink (54)	52	PS, thoracic pain, platelet Cyfra 21-1 and TPA: ↓survival	PS, platelet count, Cyfra 21-1: ↓survival

CEC, circulating endothelial cells; NLR, neutrophil/lymphocyte ratio; NTS, neurotensin; PLGF, placental growth factor; TN, tumor necrosis; MVC, microvessel count; MVD, microvessel density

Molecular/pathologic prognostication

There are a multitude of studies investigating single or multiple genes in tissue, proteins, or circulating blood based biomarkers for predicting MPM survival (Table 3). Global molecular prognostication of mesothelioma using gene expression array technology was first performed by Gordon *et al.* (55) using the 12,000 U95 Affymetrix gene chip. A four-gene expression ratio test was able to predict treatment-related patient outcome in mesothelioma, independent of the histologic subtype of the tumor. In a follow-up publication, these MPM prognostic genes and gene ratio-based prognostic tests predicted clinical outcome in a separate cohort of 39 independent MPM tumor specimens in a statistically significant manner (40). Using similar technology, Pass *et al.* (56) have reported a 27-gene expression array for mesothelioma prognostication. The groups predicted by the gene classifier recapitulated the actual time to progression and survival of the test set with 95.2% accuracy using tenfold cross validation. There has, however, been variability in the gene sets and results of these prognostic tests when used in other MPM cohorts. Affymetrix U133A microarray analysis on 99 pleural mesotheliomas from the Memorial Sloan-Kettering (MSK) Cancer Center revealed that advanced-stage, sarcomatous histology and P16/CDKN2A homozygous deletion to

be significant, independent, adverse prognostic factors. Examination of the gene expression correlates of survival showed that more aggressive mesotheliomas expressed higher levels of Aurora kinases A and B. Moreover, evaluation of three recently published microarray-based outcome prediction models in the MSK cohort revealed accuracies from 63% to 67%, consistently lower than reported (47). At present, there are no validated gene sets for prognostication of MPM. Tumor tissue examination has revealed the presence of a single microRNA, mir-29c*, to be associated with improved time to progression and overall survival, but needs further validation (38). High nuclear grade has also been associated with poor survival in multivariate analyses (33). Some of the more recently published blood-based biomarkers have included neutrophil lymphocyte ratios (25,31,32) demonstrating poor prognosis for those patients having a low ratio, as well as elevated levels of SMRP and osteopontin showing correlation with shorter survival (46). Circulating endothelial cell (CEC) count has been positively correlated with intratumoral microvessel density and an elevated CEC count was significantly associated with a poor prognosis. Moreover, a multivariate analysis showed that higher CEC count was a significant and independent factor to predict a poor prognosis (24).

The future of prognostic biomarkers in MPM will most

likely involve a multi-institutional consortium of centers which will harvest tissue, blood and other specimens in a protocol using the same standard operating procedures in order to minimize extraneous differences which could lead to false positive results. As new platforms develop, including analysis of other short RNA species, autoantibodies, and circulating tumor cells, along with new therapies, it will be crucial to make sure that an ongoing registry which incorporates robust demographics as well as documentation of specimen archiving be available to the Mesothelioma community. At this time the National Mesothelioma Virtual Tissue Bank (57) fulfills that role in the United States, and is adding new sites to ensure that reagents and tissues for MPM prognostication will be available.

Acknowledgements

Disclosure: Research Funding from NCI/NIH, DOD, CDC, Covidien, Mensanna, Rosetta Genomics, SomaLogic, Celera, SourceMDx, Fujirebio, Pfizer, Response Genetics, Meso Scale Diagnostics, Integrated Diagnostics, Transgenomics, Belluck and Fox, Stephen Banner Lung Foundation, Simmons Mesothelioma Foundation, Levi Phillips Konigsberg.

Medical Advisory Boards for Rosetta Genomics, Prometheus, Champions, Pinpoint Genomics, Precision Therapeutics, and GSK.

Research collaborations with Foundation Medicine, Response Genetics, Cynvezio.

Patents for use of osteopontin for diagnosis of mesothelioma; pending for microRNA for diagnosis/prognosis of mesothelioma; pending for EFEMP1 and mesothelioma diagnosis/prognosis.

References

- Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol* 2003;21:2636-44.
- van Meerbeeck JP, Scherpereel A, Surmont VF, et al. Malignant pleural mesothelioma: the standard of care and challenges for future management. *Crit Rev Oncol Hematol* 2011;78:92-111.
- Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. *Chest* 1995;108:1122-8.
- Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. *J Thorac Cardiovasc Surg* 2008;135:620-6, 626.
- Edwards JG, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. *Thorax* 2000;55:731-5.
- Nojiri S, Gemba K, Aoe K, et al. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. *Jpn J Clin Oncol* 2011;41:32-9.
- Tanrikulu AC, Abakay A, Kaplan MA, et al. A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma. *Respiration* 2010;80:480-7.
- Richards WG, Godleski JJ, Yeap BY, et al. Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases. *Cancer* 2010;116:1510-7.
- Francart J, Vaes E, Henrard S, et al. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials. *Eur J Cancer* 2009;45:2304-11.
- Yan TD, Boyer M, Tin MM, et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. *J Thorac Cardiovasc Surg* 2009;138:619-24.
- Gonlugur U, Gonlugur TE. Prognostic factors for 100 patients with malignant pleural mesothelioma. *Arch Environ Occup Health* 2010;65:65-9.
- Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. *J Thorac Oncol* 2007;2:957-65.
- Steele JP. Prognostic factors for mesothelioma. *Hematol Oncol Clin North Am* 2005;19:1041-52, vi.
- Neumann V, Rutten A, Scharmach M, et al. Factors influencing long-term survival in mesothelioma patients—results of the German mesothelioma register. *Int Arch Occup Environ Health* 2004;77:191-9.
- Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. *Chest* 1998;113:723-31.
- Steele JP, Rudd RM. Malignant mesothelioma: predictors

- of prognosis and clinical trials. *Thorax* 2000;55:725-6.
17. Gill RR, Richards WG, Yeap BY, et al. Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume. *AJR Am J Roentgenol* 2012;198:359-63.
 18. Sharif S, Zahid I, Routledge T, et al. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? *Interact Cardiovasc Thorac Surg* 2011;12:806-11.
 19. Lee HY, Hyun SH, Lee KS, et al. Volume-based parameter of 18F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. *Ann Surg Oncol* 2010;17:2787-94.
 20. Nowak AK, Francis RJ, Phillips MJ, et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. *Clin Cancer Res* 2010;16:2409-17.
 21. Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. *J Thorac Cardiovasc Surg* 2006;132:763-8.
 22. Gerbaudo VH, Britz-Cunningham S, Sugarbaker DJ, et al. Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma. *Thorax* 2003;58:1077-82.
 23. Pass HI, Temeck BK, Kranda K, et al. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. *J Thorac Cardiovasc Surg* 1998;115:310-7.
 24. Yoneda K, Tanaka F, Kondo N, et al. Circulating Endothelial Cell (CEC) as a diagnostic and prognostic marker in Malignant Pleural Mesothelioma (MPM). *Ann Surg Oncol* 2012;19:4229-37.
 25. Kao SC, Vardy J, Chatfield M, et al. Validation of prognostic factors in Malignant Pleural Mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. *Clin Lung Cancer* 2012. [Epub ahead of print].
 26. Cedrés S, Montero MA, Martínez P, et al. Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). *Lung Cancer* 2012;77:192-8.
 27. Burt BM, Bader A, Winter D, et al. Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation. *Clin Cancer Res* 2012;18:1568-77.
 28. Aoe K, Amatya VJ, Fujimoto N, et al. CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma. *Clin Cancer Res* 2012;18:1447-56.
 29. Levallet G, Vaisse-Lesteven M, Le SN, et al. Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group. *J Thorac Oncol* 2012;7:599-606.
 30. Kao SC, Armstrong N, Condon B, et al. Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma. *Cancer* 2012;118:2952-61.
 31. Kao SC, Klebe S, Henderson DW, et al. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. *J Thorac Oncol* 2011;6:1923-9.
 32. Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. *Clin Cancer Res* 2010;16:5805-13.
 33. Kadota K, Suzuki K, Colovos C, et al. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. *Mod Pathol* 2012;25:260-71.
 34. Burt BM, Rodig SJ, Tilleman TR, et al. Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. *Cancer* 2011;117:5234-44.
 35. Gaafar R, Bahnassy A, Abdelsalam I, et al. Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. *Lung Cancer* 2010;70:43-50.
 36. Alifano M, Loi M, Camilleri-Broet S, et al. Neurotensin expression and outcome of malignant pleural mesothelioma. *Biochimie* 2010;92:164-70.
 37. Schramm A, Opitz I, Thies S, et al. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. *Eur J Cardiothorac Surg* 2010;37:566-72.
 38. Pass HI, Goparaju C, Ivanov S, et al. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. *Cancer Res* 2010;70:1916-24.
 39. Pompeo E, Albonici L, Doldo E, et al. Placenta growth factor expression has prognostic value in malignant pleural mesothelioma. *Ann Thorac Surg* 2009;88:426-31.
 40. Gordon GJ, Dong L, Yeap BY, et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. *J Natl Cancer Inst* 2009;101:678-86.
 41. Schneider J, Hoffmann H, Dienemann H, et al. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. *J Thorac Oncol* 2008;3:1317-24.

42. Roe OD, Creaney J, Lundgren S, et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. *Lung Cancer* 2008;61:235-43.
43. Christensen BC, Godleski JJ, Roelofs CR, et al. Asbestos burden predicts survival in pleural mesothelioma. *Environ Health Perspect* 2008;116:723-26.
44. Baldi A, Mottolese M, Vincenzi B, et al. The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. *Pharmacogenomics* 2008;9:1069-77.
45. Edwards JG, Swinson DE, Jones JL, et al. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. *Lung Cancer* 2006;54:399-407.
46. Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. *Clin Cancer Res* 2007;13:2928-35.
47. López-Ríos F, Chuai S, Flores R, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. *Cancer Res* 2006;66:2970-9.
48. Edwards JG, Swinson DE, Jones JL, et al. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. *Chest* 2003;124:1916-23.
49. Baldi A, Santini D, Vasaturo F, et al. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. *Thorax* 2004;59:428-33.
50. Edwards JG, Faux SP, Plummer SM, et al. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. *Clin Cancer Res* 2002;8:1857-62.
51. Edwards JG, Cox G, Andi A, et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. *Br J Cancer* 2001;85:863-8.
52. Procopio A, Strizzi L, Vianale G, et al. Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. *Genes Chromosomes Cancer* 2000;29:173-9.
53. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. *Br J Cancer* 1999;81:54-61.
54. Schouwink H, Korse CM, Bonfrer JM, et al. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. *Lung Cancer* 1999;25:25-32.
55. Gordon GJ, Jensen RV, Hsiao LL, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. *J Natl Cancer Inst* 2003;95:598-605.
56. Pass HI, Liu Z, Wali A, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. *Clin Cancer Res* 2004;10:849-59.
57. Amin W, Parwani AV, Schmandt L, et al. National Mesothelioma Virtual Bank: a standard based biospecimen and clinical data resource to enhance translational research. *BMC Cancer* 2008;8:236.

Cite this article as: Pass HI. Biomarkers and prognostic factors for mesothelioma. *Ann Cardiothorac Surg* 2012;1(4):449-456. DOI: 10.3978/j.issn.2225-319X.2012.10.04